United States · Research startup

unlearn.ai

Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts.

Funding reportedLast round: Series C

ResearchSan Francisco, United States

About unlearn.ai

Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts.

The company specializes in the intersection of artificial intelligence, biostatistics, and clinical research, focusing on the development of digital twins to enhance clinical trials. Unlearn.AI aims to make clinical trials smarter, faster, and more efficient by eliminating traditional trial and error methods in medicine. The company offers AI-powered digital twins that serve as statistical forecasts for clinical trial participants, replacing traditional placebo groups. Its key products include TwinRCTTM, a suite of statistical methods that enables smaller, more efficient trials, and PROCOVATM, a patent-pending method that adjusts for prognostic covariates to optimize sample sizes. Unlearn.AI's technology helps pharmaceutical and biotech companies reduce trial timelines, lower costs, and address ethical concerns related to placebo use, ultimately accelerating the delivery of life-saving treatments.

What company datasets say unlearn.ai raised

Funding, as reported

Reported in all$135Min dollars
Rounds7
Last roundSeries C
Last round size$50M
Last round dateFeb 2024
Investors listed15
SEC Form D$127M sold, 4 filings, last Feb 2024

Founders and team

From unlearn.ai's own website and the SEC filings it signed: 2 founders, 6 on the team.

Jon WalshFounder & Chief Scientific Officer
Aaron SmithFounder & Head of AINamed on its 2024 Form D
  • Steve HerneChief Executive Officer
  • Andrew StelzerChief Commercial Officer
  • Prathyusha DuraibabuChief Financial & Operating Officer
  • Andrew GillExecutive Officeri
  • Charles FisherExecutive Officer, Directori
  • John McGovernExecutive Officeri

On the board, as filediAnn TaylorEric ShiozakiErmira Murati

On 3 portfolio pages

Investors who name them

Each firm lists unlearn.ai on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

The company, in detail

What they build

Known for

health careai for clinical data integrationcross-functional collaborationai in neurodegenerative diseasesclinical trial predictive toolsclinical trial success optimizationai for trial design in neurologypatient outcome predictionai in rare diseasesai-driven trial designdata sciencesingle-arm studiesenterprisesai for safety signal detectionai for placebo control reductionmedical research

Built with from their website

Amazon SESGoogle Tag ManagerAmazon CloudFrontWordPress.orgAtlassianYouTubeMailChimpGoogle WorkspaceCloudFlareViewport Meta

+8 more

Google DriveAmazon Simple Email ServiceHubspotWebflow HostingAIGoogle MeetNetSuiteCloudFlare CDN

Sector
Research
Industry code
NAICS 54171, 51321, SIC 8731, 7372
Region
California
Revenue
$5.4M a year, as listed
Full record
Every detail in the company directory

Research in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put unlearn.ai in front of investors. Or tell us what we have wrong.